Per- and polyfluoroalkyl substances (PFAS) alter immune responses from THP-1 human monocytes

Read full text
Authors: Jennifer R. McCall, Kathryn T. Sausman, Ralph N. Mead
Cited by: 6
References: 54

Abstract

Per- and Polyfluoroalkyl substances (PFAS) are widespread environmental contaminants linked to various adverse health conditions, including immune dysregulation and inflammation, though cellular mechanisms remain poorly understood. In this study, we investigated the direct in vitro impact of long-chain/legacy PFOA and PFOS, byproduct NBP2, PFO4DA, and PFMOAA, and next generation HFPO-DA/”GenX” on THP-1 human monocyte function at the cellular level . While all PFAS activated THP-1 cells and altered immune function, it is important to note that they did so in very different and often contrasting ways. PFOS suppressed inflammatory cytokine release, while NBP2 and PFO4DA activated uncoordinated and simultaneous inflammatory and anti-inflammatory immune responses. PFOA, HFPO-DA/”GenX”, and PFMOAA increased markers of suppressive phenotypes often associated with tumor-associated macrophages. Taken together, our findings demonstrate that PFAS, even at non-lethal concentrations, can directly interfere with functional immune responses in cellular models by altering cytokine profiles and immune activation states. • Individual PFAS alter immune responses in very different, sometimes opposing, ways. • Different PFAS caused immune suppression, inflammation, and/or tumor promoting phenotypes. • All PFAS increased size and complexity of THP-1 monocytes, indicating immune cell activation. • PFOS suppressed cytokine secretion but resulted in intracellular cytokine retention. • Byproducts NBP2 and PFO4DA caused uncoordinated monocyte responses to stimuli.

Fields of Study & Subjects

Per- and polyfluoroalkyl substances research Toxic Organic Pollutants Impact Fluorine in Organic Chemistry

Publication details

Journal / source
Environmental Toxicology and Pharmacology
Publisher
Elsevier BV
Volume
122
Pages
104938–104938
Publication date
10 January 2026
Language
EN